Fastest Growing Stocks
UCB.BR is part of our fastest growing stocks screen, indicating it has high EPS and sales growth.
UCB SA (UCB.BR) Stock Price & Overview
EBR:UCB • BE0003739530
Current stock price
231.2 EUR
+5 (+2.21%)
Last:
The current stock price of UCB.BR is 231.2 EUR. Today UCB.BR is up by 2.21%. In the past month the price decreased by -10.56%. In the past year, price increased by 36.64%.
UCB.BR Key Statistics
52-Week Range146.05 - 289.5
Current UCB.BR stock price positioned within its 52-week range.
1-Month Range223 - 278.4
Current UCB.BR stock price positioned within its 1-month range.
- Market Cap
- 44.971B
- P/E
- 23.14
- Fwd P/E
- 21.90
- EPS (TTM)
- 9.99
- Dividend Yield
- 0.44%
UCB.BR Stock Performance
Today
+2.21%
1 Week
-6.13%
1 Month
-10.56%
3 Months
-9.48%
Longer-term
6 Months +3.91%
1 Year +36.64%
2 Years +85.63%
3 Years +173.87%
5 Years +200.03%
10 Years +253.79%
UCB.BR Stock Chart
UCB.BR Stock Screens
UCB.BR currently appears in the following ChartMill screener lists.
UCB.BR Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to UCB.BR. When comparing the yearly performance of all stocks, UCB.BR turns out to be only a medium performer in the overall market: it outperformed 68.93% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
UCB.BR Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to UCB.BR. UCB.BR gets an excellent profitability rating and is at the same time showing great financial health properties.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
UCB.BR Earnings
On February 26, 2026 UCB.BR reported an EPS of 6.46 and a revenue of 4.25B. The company beat EPS expectations (17.63% surprise) and beat revenue expectations (13.65% surprise).
Next Earnings DateJul 26, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported€6.46
Revenue Reported4.254B
EPS Surprise 17.63%
Revenue Surprise 13.65%
UCB.BR Forecast & Estimates
27 analysts have analysed UCB.BR and the average price target is 288.71 EUR. This implies a price increase of 24.88% is expected in the next year compared to the current price of 231.2.
For the next year, analysts expect an EPS growth of 5.7% and a revenue growth 11.39% for UCB.BR
Analysts
Analysts74.81
Price Target288.71 (24.87%)
EPS Next Y5.7%
Revenue Next Year11.39%
UCB.BR Index Membership
UCB.BR is currently included in the following stock indexes tracked on ChartMill.
UCB.BR Financial Highlights
Over the last trailing twelve months UCB.BR reported a non-GAAP Earnings per Share(EPS) of 9.99. The EPS increased by 100.6% compared to the year before.
Income Statements
Revenue(TTM)7.74B
Net Income(TTM)1.56B
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.13% | ||
| ROA | 8.58% | ||
| ROE | 14.34% | ||
| Debt/Equity | 0.2 |
Chartmill High Growth Momentum
EPS Q2Q%123.53%
Sales Q2Q%26.57%
EPS 1Y (TTM)100.6%
Revenue 1Y (TTM)25.83%
UCB.BR Ownership
Ownership
Inst Owners40.85%
Shares194.51M
Float119.69M
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
UCB.BR Industry Overview
UCB.BR operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 26 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Strength Score
55/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
Industry Growth Score
59/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
28%
Outperformed 28% of sub-industries
6 Month Rank
49%
Outperformed 49% of sub-industries
Industry Fundamentals & Breadth
- Members
- 26
- New Highs
- 0%
- New Lows
- 3.9%
- Average ROE
- 15.4%
- Average Profit Margin
- 17.1%
- Average Operating Margin
- 23%
- Average P/E
- 14.7
- Average Fwd P/E
- 11.8
- Average Debt/Equity
- 0.4
UCB.BR Competitors/Peers
The largest stocks on the EU markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SAN | SANOFI | 8.79 | 96.756B | ||
| SNW | SANOFI | 8.79 | 96.756B | ||
| 1SAN | SANOFI | 8.6 | 94.671B | ||
| MRK | MERCK KGAA | 13.95 | 47.848B | ||
| UNC | UCB SA | 21.24 | 43.629B | ||
| 1BAYN | BAYER AG-REG | 8.66 | 37.43B | ||
| BAYN | BAYER AG-REG | 8.65 | 37.381B | ||
| IPN | IPSEN | 13.19 | 13.996B | ||
| REC | RECORDATI INDUSTRIA CHIMICA | 16.7 | 10.381B | ||
| TUB | FINANCIERE DE TUBIZE | N/A | 8.711B | ||
| VIRP | VIRBAC SA | 17.37 | 3.117B | ||
| DMP | DERMAPHARM HOLDING SE | 18.78 | 2.495B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Brussels Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find more growth stocks the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About UCB.BR
Company Profile
UCB SA engages in the research and development of biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale and currently employs 10,117 full-time employees. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
Company Info
IPO: 1987-01-02
UCB SA
Allee de la Recherche, 60
Anderlecht BRUXELLES-CAPITALE BE
Employees: 9765
Phone: 3225599999
UCB SA / UCB.BR FAQ
What does UCB do?
UCB SA engages in the research and development of biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale and currently employs 10,117 full-time employees. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
Can you provide the latest stock price for UCB SA?
The current stock price of UCB.BR is 231.2 EUR. The price increased by 2.21% in the last trading session.
Does UCB stock pay dividends?
UCB SA (UCB.BR) has a dividend yield of 0.44%. The yearly dividend amount is currently 1.39.
How is the ChartMill rating for UCB SA?
UCB.BR has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Which stock exchange lists UCB stock?
UCB.BR stock is listed on the Euronext Brussels exchange.
How many employees does UCB SA have?
UCB SA (UCB.BR) currently has 9765 employees.
Can you provide the market cap for UCB SA?
UCB SA (UCB.BR) has a market capitalization of 44.97B EUR. This makes UCB.BR a Large Cap stock.